Related Experiment Video
Updated: Oct 13, 2025
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment
Zeyi Cheng1, Tingting Fang2, Jinglei Huang3
1Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China.
Insights
Hypertrophic cardiomyopathy (HCM), a common inherited heart disease, stems from genetic mutations affecting cardiac proteins. Research is advancing disease-specific therapies by understanding HCM
Area of Science:
- Cardiovascular Medicine
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiovascular disease affecting approximately 1 in 500 individuals.
- It arises from over 1,400 mutations in genes encoding cardiac sarcomere proteins, leading to complex pathophysiology.
- HCM is a primary cause of sudden cardiac death (SCD) in young individuals and contributes to heart failure and stroke.
Purpose of the Study:
- To review critical discoveries in the treatment and mechanisms of Hypertrophic Cardiomyopathy.
- To highlight the implications of genetic insights for future research and therapeutic development in HCM.
- To provide an overview of current therapeutic strategies and their limitations.
Main Methods:
- Literature review focusing on genetic landscape, molecular pathogenesis, and treatment modalities of HCM.
- Analysis of current therapeutic approaches including medication, surgical, and interventional procedures.
- Synthesis of research findings to identify potential therapeutic targets and future research directions.
Main Results:
- Genetic insights have significantly improved the understanding of HCM's molecular pathogenesis.
- Current treatments primarily focus on symptom relief and disease progression, with limited disease-specific options.
- Translational research is yielding promising avenues for novel, targeted therapies for HCM.
Conclusions:
- Advances in understanding the genetic basis of HCM are paving the way for disease-specific treatments.
- Future research should focus on translating genetic discoveries into effective therapeutic agents.
- Targeted therapies hold promise for improving outcomes and preventing adverse events in HCM patients.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a very common inherited cardiovascular disease (CAD) and the incidence is about 1/500 of the common population. It is caused by more than 1,400 mutations in 11 or more genes encoding the proteins of the cardiac sarcomere. HCM presents a heterogeneous clinical profile and complex pathophysiology and HCM is the most important cause of sudden cardiac death (SCD) in young people. HCM also contributes to functional disability from heart failure and stroke (caused by atrial fibrillation). Current treatments for HCM (medication, myectomy, and alcohol septal ablation) are geared toward slowing down the disease progression and symptom relief and implanted cardiac defibrillator (ICD) to prevent SCD. HCM is, however, entering a period of tight translational research that holds promise for the major advances in disease-specific therapy. Main insights into the genetic landscape of HCM have improved our understanding of molecular pathogenesis and pointed the potential targets for the development of therapeutic agents. We reviewed the critical discoveries about the treatments, mechanism of HCM, and their implications for future research.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:25Cardiomyopathy I: Introduction and Classification
01:17Pathophysiology of Heart Failure
01:29Heart Failure II: Pathophysiology
01:30Cardiomyopathy II: Dilated Cardiomyopathy